Application of glycerol triacetate in preparation of medicine for preventing and treating depression

A technology for triacetin and depression, which is used in drug combinations, ester active ingredients, nervous system diseases, etc., can solve the problems of slow onset, large side effects, and unclear pathophysiological mechanisms, and achieves prevention and treatment of depression. symptoms, improvement of depressive-like behaviors

Inactive Publication Date: 2020-04-21
FUJIAN MEDICAL UNIV UNION HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, despite decades of research, its pathophysiological mechanism is still unclear, and there is still a lack of particularly effective treatment methods. The current treatment strategies for depression mainly include drug therapy, psychosocial therapy, and electroconvulsive therapy. Drug therapy is the mainstay, but the clinically available antidepressant drugs have great limitations, including: slow onset of action, large side effects and low effective rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glycerol triacetate in preparation of medicine for preventing and treating depression
  • Application of glycerol triacetate in preparation of medicine for preventing and treating depression
  • Application of glycerol triacetate in preparation of medicine for preventing and treating depression

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 GTA acute administration antidepressant experiment.

[0029] 8-10 week-old clean-grade healthy male C57 mice were supplemented with GTA (3g / kg) for 0.5h, 1h, 2h, and 4h, and their performance in forced swimming was detected immediately, and then the hippocampal tissue of the mouse brain was harvested. The results showed that the administration group was compared with the control group, such as figure 1 -A, Immobility time in forced swimming was significantly reduced after GTA (3g / kg / d) supplementation for 1h and 2h; as figure 2 -B, and the level of acetyl-CoA in the hippocampus reached its peak after supplementing GTA (3g / kg / d) for 1h and 2h; figure 1 -C is 8-10 weeks old clean-grade healthy male C57 mice were given GTA 1g / kg, 2g / kg, 3g / kg, 4g / kg and immediately detected their performance in forced swimming, the results showed that when the dose When it was 3g / kg, the immobility time of mice in forced swimming was the shortest.

Embodiment 2

[0030] Example 2 Preventive GTA supplementation antidepressant experiment.

[0031] like figure 2 -A, the level of acetyl-CoA in the prefrontal cortex of the mice after half an hour of exogenous supplementation of GTA (administration) in clean-grade healthy male C57 mice at the age of 8-10; figure 2 -B and figure 2 -C, The level of acetyl-CoA in the prefrontal cortex and hippocampus of mice susceptible to social stress (model) was significantly reduced, while the level was roughly restored to normal after exogenous supplementation of GTA (administration).

[0032] 60 clean healthy male C57BL / 6J mice aged 8-10 weeks, weighing 22±2g, were randomly divided into 4 groups, 15 mice in each group, respectively blank control group, depression model group, depression model + GTA group, depression model group Model + fluoxetine group. like image 3 As shown in -A, the four groups of animals were given the corresponding drugs by intragastric administration, once a day, for 10 cons...

Embodiment 3

[0036] Example 3 Therapeutic Supplement GTA Antidepressant Experiment.

[0037] 8-10 weeks old clean grade healthy male C57BL / 6J mice were induced to exhibit depression-like behavior through social stress model, such as Image 6 -A, after 3 days of therapeutic supplementation of GTA (3g / kg / d) to depressed mice, the depression-like behavior of the mice was detected on the 4th day. On the 22nd day, the hippocampus tissue samples were collected for Golgi staining and western blotting.

[0038] The depressive-like behavior of the mice was detected on the 4th day, and the results showed that the depressive-like behavior of the depressed mice was improved after therapeutic GTA supplementation, as shown in Image 6 Decreased time spent immobilized in the forced swim test (FST) as indicated by -D; as Image 6 As shown by -E, there is an enhancement of sugar water preference; as Image 6 -F, Image 6 -G shows that the percentage of time spent in the central area increased and the p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for preventing and treating depression. The composition comprises glycerol triacetate. The inventor finds out a novel application of glycerol triacetate. After glycerol triacetate is supplemented in a preventive and therapeutic manner, depressive behaviors of mice can be obviously improved, namely, the glycerol triacetate has the effect of preventing and treating depression.

Description

technical field [0001] The present disclosure relates to a new use of triacetin, in particular to a use of triacetin in the preparation of drugs for preventing and treating depression. Background technique [0002] Major depressive disorder (MDD) is a serious and ubiquitous disease characterized by high prevalence, high relapse rate, high disability rate, and high suicide rate. Major symptoms are the basic features. According to the World Health Organization (WHO), as of 2012, it affects 350 million people around the world, and the number of suicide deaths due to depression exceeds 1 million every year, which brings a heavy burden to society and will It will become one of the top five health burdens worldwide in 2030. However, despite decades of research, its pathophysiological mechanism is still unclear, and there is still a lack of particularly effective treatment methods. The current treatment strategies for depression mainly include drug therapy, psychosocial therapy, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/22A61P25/24
CPCA61K31/22A61P25/24
Inventor 张静陈晓春黄炜彬
Owner FUJIAN MEDICAL UNIV UNION HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap